TetraLogic to Present at the 14th Annual Needham Healthcare Conference
09 Avril 2015 - 4:11PM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that J. Kevin Buchi, President and Chief Executive
Officer, will present at the 14th Annual Needham Healthcare
Conference on Wednesday, April 15, 2015 at 10:00 a.m. Eastern Time
at the Westin Grand Central Hotel in New York. Mr. Buchi will
provide an overview of the Company and its corporate activities.
The presentation will be webcast live and may be accessed by
visiting TetraLogic's website at http://ir.tetralogicpharma.com/. A
replay of the webcast will be available for 90 days.
About TetraLogic Pharmaceuticals
Corporation
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics in
oncology and infectious diseases. TetraLogic has two clinical-stage
product candidates in development: birinapant and SHAPE. Birinapant
is currently being tested in Phase 1 and Phase 2 clinical trials
for hematological malignancies and solid tumors, and is also being
tested in a Phase 1b/2a clinical trial in hepatitis B. SHAPE is
currently being tested in a Phase 2 clinical trial for early-stage
cutaneous T‑cell lymphoma.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future events
or TetraLogic's pre-clinical and clinical development of
birinapant, SHAPE and other clinical programs, future expectations,
plans and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under the heading "Risk
Factors" in our Annual Report on Form 10-K filed with the U.S.
Securities and Exchange Commission (SEC) on February 26, 2015. Any
forward-looking statements contained in this release speak only as
of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT: Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024